Brugada syndrome is an inherited arrhythmogenic disease that may cause sudden cardiac death due to ventricular fibrillation in young adults. Brugada syndrome caused by propafenone intoxication has been noted rarely in the literature. We report a rare case, Brugada phenocopy due to propafenone intoxication and its treatment. A 15-year-old girl having a seizure was brought to the emergency room. She took 1.5 g propafenone (Rythmol, Abbott, Chicago, IL, USA) for suicidal intention. She had metabolic acidosis. Long QRS interval and ST elevation in leads V1 through V3 were seen on electrocardiography. After bicarbonate infusion for 4 hours, haemodynamic and neurologic findings were recovered, and all electrocardiography abnormalities disappeared. The Brugada-like electrocardiography pattern was not recognized in her surface and 24-hour Holter electrocardiography at follow-up. Ajmaline challenge test was negative 2 weeks later. Absence of symptoms and documented ventricular tachycardia, negative challenge test, and a negative family history demonstrated that the Brugada phenocopy was a transient finding in this case and related to propafenone intoxication.
Background: Tricuspid regurgitation (TR) is increasingly recognized as a detectable finding during routine fetal echocardiography. Although previous studies have explored its potential role as an indirect marker for congenital heart disease (CHD) in the first trimester, the prognostic significance of isolated mild TR in chromosomally normal and low-risk fetuses during the second and third trimesters remains unclear. Clarifying the clinical relevance of this commonly encountered Doppler finding is essential to guide appropriate prenatal management and avoid unnecessary interventions in low-risk pregnancies. Materials and Methods: This retrospective study reviewed fetal echocardiography reports of 1592 pregnant women referred to a pediatric cardiology clinic after the 20th gestational week between 1 January 2024 and 1 January 2025. Following exclusion criteria, 1072 low-risk pregnancies were included. A total of 136 fetuses with TR were identified, and among them, postnatal echocardiographic outcomes of 60 neonates who underwent transthoracic echocardiography within the first 10 days after birth were analyzed. Results: Among the 1072 low-risk pregnancies included in the study, a total of 136 fetuses were diagnosed with TR on fetal echocardiography. The majority of these cases were characterized as mild and isolated, without accompanying structural abnormalities. Postnatal echocardiographic assessments revealed no major congenital cardiac anomalies, reinforcing the interpretation that isolated mild TR in the context of low-risk pregnancies represents a benign and likely transient physiological finding. Conclusion: Isolated mild TR, particularly in low-risk and chromosomally normal pregnancies, appears to be a transient and clinically insignificant finding. These results support the interpretation of fetal TR in the context of overall clinical and structural evaluation, helping to avoid unnecessary interventions and reduce parental anxiety.
1 September 2014 in Klinik Psikofarmakoloji Bülteni / Bulletin of Clinical Psychopharmacology
Objectives: Cardiovascular adverse effects can be seen rarely in patients receiving methylphenidate for attention deficit and hyperactivity disorder (ADHD). In this study, we planned to investigate the effects of methylphenidate on the cardiovascular system in ADHD patients. Methods: One hundred and forty-one patients, who were diagnosed with ADHD and started on methylphenidate treatment between May 2011 and May 2012, were investigated. A cardiologic evaluation was performed on all of the patients before the methylphenidate treatment was begun. Subsequently, the patients were invited for regular visits at three months intervals for assessment of cardiovascular and electrocardiographic (ECG) changes during this treatment. The data of all these patients at the beginning of treatment and within the first 6 months were evaluated. Thirty-five patients (24.8%) suffered from various cardiovascular symptoms in the first 6 months. Demographic characteristics, heart rate, systolic and diastolic blood pressures, QTc duration on ECG, rhythm Holter and 24-hour blood pressure monitoring results of these patients were evaluated. Results: Thirty-five patients (10 girls and 25 boys) had cardiovascular symptoms in the first 6 months. The mean age of patients was 9.2±2.8 years. Although QTc duration significantly increased after methylphenidate treatment (p<0.05), this increase was within normal ranges. Similarly, systolic and diastolic blood pressures of patients increased significantly. This increase was between the 90–95th percentiles in only 5 patients. Twenty-four-hour blood pressure monitoring results were normal, and the methylphenidate treatment of these patients was not stopped. The mean heart rate of patients was also increased, but this increase was not statistically significant. The symptoms with respect to the cardiovascular system were palpitations in 16 patients (45.8%), chest pain in 11 patients (31.5%), palpitations with chest pain in 5 patients (14.2%) and dyspnea in 3 patients (8.5%). All patients' ECG and rhythm Holter results were within normal limits. Two patients discontinued treatment because of their parent's unwillingness for the drug to be continued. Conclusions: In ADHD patients, the elongation of QTc duration and increase in the systolic and diastolic blood pressures were statistically significant during 6 months of methylphenidate treatment. However, all these changes remained within normal limits. All patients receiving this drug should be monitored carefully for cardiovascular side effects.